Climb Bio to Unveil Key Data on CLYM116 and Budoprutug at ASN Kidney…

Event summary

Climb Bio will present new clinical data for CLYM116 and budoprutug at ASN Kidney Week 2026, held in Denver from October 21-25, 2026.
Preliminary Phase 2 data from the PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation.
CLYM116 Phase 1 safety and tolerability data to be presented in two poster sessions.
Budoprutug data includes a case study on durable response in minimal change disease.

The big picture

Climb Bio's presentations at ASN Kidney Week 2026 come at a critical juncture for its pipeline, particularly as it seeks to differentiate budoprutug and CLYM116 in crowded immune-mediated disease markets. The company's focus on kidney diseases positions it in a growing segment of biotech innovation, where targeted therapies are increasingly gaining traction. The strategic anomaly here is the dual-pronged approach of advancing both a novel anti-APRIL antibody and a low-fucosylated anti-CD19 monoclonal antibody, a move that could either diversify risk or stretch resources thin.

What we're watching

Clinical Efficacy: How the Phase 2 data for budoprutug in primary membranous nephropathy will impact its development trajectory.
Regulatory Pathway: Whether the FDA's Orphan Drug and Fast Track designations for budoprutug will accelerate approval timelines.
Market Differentiation: The pace at which CLYM116's 'sweeper' mechanism can establish a competitive advantage in IgA nephropathy.